1,123
Views
14
CrossRef citations to date
0
Altmetric
Review

Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis

, , , , , , , & show all
Pages 619-629 | Published online: 10 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Agne Paner, Tochukwu M. Okwuosa, Kristin J. Richardson & Edward N. Libby. (2018) Triplet therapies – the new standard of care for multiple myeloma: how to manage common toxicities. Expert Review of Hematology 11:12, pages 957-973.
Read now

Articles from other publishers (13)

V. Leclerc, L. Karlin, C. Herledan, L. Marchal, A. Baudouin, A. Gouraud, A. G. Caffin, V. Larbre, A. Lazareth, E. Bachy, G. Salles, H. Ghesquières, C. Rioufol & F. Ranchon. (2021) Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study. Journal of Cancer Research and Clinical Oncology 148:4, pages 975-984.
Crossref
Fehaid Alanazi, Faith A.A. Kwa, Genia Burchall & Denise E. Jackson. (2020) New generation drugs for treatment of multiple myeloma. Drug Discovery Today 25:2, pages 367-379.
Crossref
Dikélélé Elessa, Alexis Talbot, Naëlle Lombion, Stéphanie Harel, Lionel Galicier, Agnès Veyradier, Bérangère Joly, Annalisa Andreoli, Sophie Rigaudeau, Élie Azoulay, Paul Coppo, Bruno Royer & Bertrand Arnulf. (2019) Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature. British Journal of Haematology 188:2, pages 338-340.
Crossref
Shereef Elmoamly, Mervat Mattar, Maha F. Yacoub & Alaa Afif. (2019) Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies?. Acta Haematologica 141:4, pages 245-253.
Crossref
Natasha Kekre & Jean M. Connors. (2019) Venous thromboembolism incidence in hematologic malignancies. Blood Reviews 33, pages 24-32.
Crossref
Hailey A. Baker, Alexandra R. Brown, Jonathan D. Mahnken, Theresa I. Shireman, Carol E. Webb & Brea C. Lipe. (2019) Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation. Cancer Medicine 8:1, pages 455-462.
Crossref
Heinz Ludwig, Meletios-Athanasios Dimopoulos & Evangelos Terpos. 2018. Multiple Myeloma and Other Plasma Cell Neoplasms. Multiple Myeloma and Other Plasma Cell Neoplasms 141 156 .
Eileen Mary Boyle, Thierry Facon, Maria Victoria Mateos & Antonio Palumbo. 2018. Multiple Myeloma and Other Plasma Cell Neoplasms. Multiple Myeloma and Other Plasma Cell Neoplasms 61 71 .
Anetta Undas, Lidia Zubkiewicz-Usnarska, Grzegorz Helbig, Dariusz Woszczyk, Justyna Kozińska, Anna Dmoszyńska, Jakub Dębski, Maria Podolak-Dawidziak & Kazimierz Kuliczkowski. (2015) Induction therapy alters plasma fibrin clot properties in multiple myeloma patients. Blood Coagulation & Fibrinolysis 26:6, pages 621-627.
Crossref
Eileen M. Boyle, Charline Legrand, Hélène Demarquette, Stéphanie Guidez, Charles Herbaux, Xavier Leleu & Thierry Facon. 2015. Handbook of Multiple Myeloma. Handbook of Multiple Myeloma 41 63 .
Joanna Rupa-Matysek, Lidia Gil, Ewelina Wojtasińska, Adam Nowicki, Dominik Dytfeld, Maciej Kaźmierczak & Mieczysław Komarnicki. (2014) Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma. Thrombosis Research 134:2, pages 404-411.
Crossref
Anetta Undas, Lidia Zubkiewicz-Usnarska, Grzegorz Helbig, Dariusz Woszczyk, Justyna Kozińska, Anna Dmoszyńska, Maria Podolak-Dawidziak & Kazimierz Kuliczkowski. (2014) Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma. European Journal of Clinical Investigation 44:6, pages 557-566.
Crossref
Guillemette Fouquet, Stéphanie Tardy, Hélène Demarquette, Sarah Bonnet, Julie Gay, Houria Debarri, Charles Herbaux, Stéphanie Guidez, Jessica Michel, Aurore Perrot, Caroline Serrier, Darko Miljkovic, Hervé Avet Loiseau, Thierry Facon, Cyrille Hulin & Xavier Leleu. (2013) Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. Cancer 119:20, pages 3680-3686.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.